US8784833B2 - Prenatal enzyme replacement therapy for hypophosphatasia - Google Patents

Prenatal enzyme replacement therapy for hypophosphatasia Download PDF

Info

Publication number
US8784833B2
US8784833B2 US13/007,772 US201113007772A US8784833B2 US 8784833 B2 US8784833 B2 US 8784833B2 US 201113007772 A US201113007772 A US 201113007772A US 8784833 B2 US8784833 B2 US 8784833B2
Authority
US
United States
Prior art keywords
tnsalp
fusion protein
fetus
embryo
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/007,772
Other versions
US20110300143A1 (en
Inventor
William S. Sly
Jeffrey H. Grubb
Shunjl Tomatsu
Adriana Maria Monta{umlaut over (n)}o Suarez
Hirotaka Oikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Original Assignee
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/769,693 external-priority patent/US7871624B2/en
Application filed by St Louis University filed Critical St Louis University
Priority to US13/007,772 priority Critical patent/US8784833B2/en
Assigned to SAINT LOUIS UNIVERSITY reassignment SAINT LOUIS UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SLY, WILLIAM S., MONTANO SUAREZ, ADRIANA MARIA, TOMATSU, SHUNJI, OIKAWA, HIROTAKA, GRUBB, JEFFREY H.
Publication of US20110300143A1 publication Critical patent/US20110300143A1/en
Priority to PCT/US2012/021507 priority patent/WO2012099851A2/en
Application granted granted Critical
Publication of US8784833B2 publication Critical patent/US8784833B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031Beta-glucuronidase (3.2.1.31)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/809Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Definitions

  • ERTs enzyme replacement therapies
  • Those diseases include Gaucher, Krabbe, Fabry and Pompe diseases, as well as various mucopolysaccharidoses (MPS) and hypophosphatasia (HPP).
  • MPS mucopolysaccharidoses
  • HPP hypophosphatasia
  • HPP is an inherited metabolic disorder that features rickets or osteomalacia caused by deficiency of tissue-nonspecific alkaline phosphatase (TNSALP; EC 3.1.3.1).
  • TNSALP is an ubiquitous, cytosol-insoluble plasma membrane-bound enzyme.
  • the human enzyme contains 524 amino acid residues, and the sequence is available on the UniProtKB/Swiss-Prot data base under the designation “PPBT-Human P05186”.
  • Hypophosphatasia is an inherited metabolic disorder of defective bone mineralization caused by deficiency of the TNSALP. Clinical severity is remarkably variable, ranging from death in utero to merely premature loss of dentition in adult life. Despite the presence of TNSALP in bone, kidney, liver, and adrenal tissue in healthy individuals, clinical manifestations in patients with hypophosphatasia are limited to defective skeletal mineralization that manifests as rickets in infants and children and osteomalacia in adults.
  • Acidic amino acid (AAA) oligopeptides bind specifically to bone matrix, hydroxyapatite calcium site, and tagging a therapeutic agent, namely TNSALP, with AAA markedly enhances delivery of the agent to bone [Nishioka et al., (2006) Mol Genet Metab, 88 (3):244-255].
  • ERT has been successively shown by a deca-Asp (D 10 )-tagged TNSALP (sALP-FcD 10 ) in a HPP murine model (similar to the infantile form in human patients) to lead to marked clinical and pathological improvement [Milian et al., (2008) J Bone Miner Res, 23 (6):777-787].
  • the sALP-FcD 10 enzyme is now used in Phase I and II clinical trials for HPP patients, resulting in substantial reversal of bone hypomineralization [Whyte et al., Hypophosphatasia: Treatment of Life-Threatening Disease Using Bone-Targeted Human Recombinant Tissue Non-Specific Alkaline Phosphatase (2009) ACR/ARHP Scientific Meeting, found at acr.confex.com/acr/2009/webprogram/Paper12463.html.
  • This sALP-FcD 10 enzyme also includes the Fc region of human IgG at the C-terminus of the enzyme for purification purposes.
  • ⁇ -glucuronidase is a cytosol- and water-soluble, sialic acid-containing glycoprotein enzyme that catalyzes breakdown of complex carbohydrates. Maternal IgG is transported transplacentally by the neonatal Fc receptor, which recognizes the Fc domain of IgG and mediates transcytosis from maternal to fetal circulation.
  • polypeptides that are linked to an immunoglobulin fraction-crystallizable domain are able to cross the placenta and to enter the circulation of the fetus.
  • Fc-domain immunoglobulin fraction-crystallizable domain
  • one aspect of the invention contemplates a fusion protein comprised of a polypeptide peptide-bonded to a Fc-domain.
  • a preferred polypeptide has a therapeutic use, such as a metabolic enzyme.
  • a more preferred polypeptide is a cytosol-soluble (water-soluble) portion of a membrane-bound enzyme.
  • a most preferred polypeptide is a tissue-nonspecific alkaline phosphatase (TNSALP).
  • compositions that comprise an effective amount of an above-described fusion protein dissolved or dispersed in a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier is typically an isotonic aqueous buffer.
  • Yet another aspect of the invention contemplates transplacental enzyme replacement therapy (ERT) for deficiency of a polypeptide such a TNSALP by administering a before-described pharmaceutical composition to a pregnant animal whose fetus or embryo is in need of such therapy.
  • An exemplary fusion protein of such a composition comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion.
  • Administration may be by any route, preferably intravenous or intraperitoneal administration of the fusion protein.
  • Inborn errors of metabolism comprise diseases, which include MPS (such as MPS VII) and hyphosphatasia.
  • the fusion protein (also some times referred to herein as a chimeric polypeptide) has a therapeutic domain and a Fc-domain as described herein.
  • FIG. 1 is a graphic representation of the results of transplacental transfer of TNSALP-Fc after intravenous infusion into pregnant mice.
  • FIG. 2 is a schematic drawing showing TNSALP-hFc constructions in mammalian expression vector pCXN.
  • FIG. 3 is a schematic drawing showing a top view of SDS-PAGE results for purified TNSALP and TNSALP-hFc.
  • FIG. 4 is a series of graphs showing the pharmacokinetics of different administration of infusions by using TNSALP-hFc.
  • a fusion protein containing the IgG Fc-domain which after infusion into the maternal circulation, mediates delivery of the fusion protein across the placenta into the circulation of the fetus or embryo.
  • An embryo is often described in the human context as existing from conception to about the eighth week, whereas a fetus is often described as being from about nine weeks to birth.
  • the present invention contemplates a fusion protein having an IgG1 Fc peptide portion peptide bonded to a water-soluble (cytosol-soluble) portion of a biologically active polypeptide that is normally membrane-bound such as tissue-nonspecific alkaline phosphatase (TNSALP) or HMG-CoA reductase.
  • TNSALP tissue-nonspecific alkaline phosphatase
  • HMG-CoA reductase HMG-CoA reductase
  • the present invention also contemplates a composition containing an effective amount of the fusion protein dissolved or dispersed in a pharmaceutically acceptable carrier.
  • a method of treating a deficiency of that biologically active polypeptide in a fetus or embryo contemplates administering the pharmaceutical composition to the pregnant animal such as a mouse or a human whose fetus or embryo is in need of the biologically active polypeptide so that the fusion protein crosses the placenta.
  • a contemplated fusion protein is dissolved, dispersed or admixed in a composition that is pharmaceutically acceptable and compatible with the active ingredient as is well known.
  • pharmaceutically acceptable or “physiologically tolerable” refer to molecular entities and compositions that typically do not produce an allergic or similar untoward reaction, and the like, when administered to a host mammal.
  • Suitable carriers can take a wide variety of forms depending on the intended use and are, for example, aqueous solutions containing saline, phosphate buffered saline (PBS), dextrose, glycerol, ethanol, or the like and combinations thereof.
  • a composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, mineral oils, which enhance the effectiveness of the composition.
  • a preferred embodiment contains at least about 0.01 percent to about 99 percent of an isolated fusion polypeptide of this invention as an active ingredient, typically at a concentration of about 10 to 200 mg of fusion protein per milliliter (ml) of carrier.
  • a contemplated composition is conventionally administered parenterally as an aqueous composition, by injection, for example, intraperitoneally, subcutaneously or intramuscularly.
  • the administration is provided to a pregnant human patient or suitable animal host such as a chimpanzee, mouse, rat, horse, sheep, mouse, dog, goat, bovine, monkey, or the like whose fetus or embryo is in need of the biologically active polypeptide.
  • a contemplated composition is thus typically provided as a unit dosage amount in dry form that can be readied for administration by addition and mixing of deionized or distilled or other sterile water.
  • the amount of fusion protein utilized in each administration is referred to as an effective amount and can vary widely, depending inter alia, upon the fusion protein, the genus of the animal to which the a fusion protein is administered, and the severity of the disease state being treated.
  • An effective amount of a fusion protein at least temporarily improves the disease state for which the fusion protein is administered.
  • heterozygous pregnant mice were infused with 10 U/g body weight of TNSALP-hFc on embryonic days 17.5 and that administration was successful in raising the level of TNSALP circulating in the fetal mice to almost twice the amount of enzyme present in untreated mice.
  • the amount selected as an effective amount of a fusion protein can be determined for a given animal host and disease by a skilled worker without undue experimentation.
  • HPP hypophosphatasia
  • a fusion protein comprising the C-terminal, hydrophobic, membrane-spanning portion of TNSALP was expressed as a fusion protein with the IgG1 CH 2 —CH 3 hFc portion (TNSALP-hFc). That fusion protein was compared with the untagged recombinant TNSALP for clearance from the maternal circulation and delivery to the fetus.
  • TNSALP-hFc To determine whether TNSALP-hFc could be transferred across the placenta, ALP activity in plasma of HPP newborns born from HPP heterozygous females mated with HPP heterozygous males was examined. It was observed that TNSALP-hFc, infused into pregnant mice on embryonic day 17.5, was transported across the placenta, whereas untagged TNSALP was not delivered to the fetus. These results are shown in FIG. 1 .
  • the C-terminus-anchorless TNSALP enzyme was produced and the secreted form tagged with CH 2 —CH 3 hFc portion to form a fusion protein that was expressed using Chinese Hamster Ovarian (CHO) cell line and showed transplacental activity in fetus on hypophosphatasia mice with ERT.
  • the present invention indicated that the enzyme with IgG1 CH 2 —CH 3 hFc portion is effective as a therapeutic agent transplacentally.
  • This method is applicable to other proteins whose deficiency leads to the other human disorders with deficiency of an enzyme such as fetal hypolipidemia using the C-terminal membrane anchor truncated HMG-CoA reductase. See, U.S. Pat. No. 5,460,949 for a useful sequence.
  • TNSALP and TNSALP-hFc were purified by the following two-step column procedure.
  • Tris buffer was 25 mM Tris-HCl, pH 8.0, containing 0.1 mM magnesium chloride and 0.01 mM zinc chloride. Unless stated otherwise, all steps were performed at 4° C. The following procedure was followed:
  • Step 1 The medium-containing enzyme was filtered through a 0.2 ⁇ m filter and then dialyzed against Tris buffer using Amicon stirred-cell ultrafiltration unit with Millipore ultrafiltration membrane YM-30.
  • Step 2 The dialyzed medium was applied to a column of DEAE-Sepharose equilibrated with Tris buffer. The column was first washed with Tris buffer and then the enzyme was eluted with 0 to 0.4 M NaCl in a linear gradient.
  • Step 3 The active eluted fractions were pooled and dialyzed against Tris buffer containing 0.1 M NaCl by using Centricon centrifugal filter device with Millipore ultrafiltration YM-10 filter. The dialyzed fractions were then concentrated for Step 4.
  • Step 4 The concentrated enzyme was applied to a column of Sephacryl S-400-HR equilibrated with Tris buffer containing 0.1 M NaCl. The enzyme was eluted with Tris buffer containing 0.1 M NaCl.
  • Step 5 The active eluted fractions were pooled and dialyzed against Tris buffer containing 0.1 M NaCl by using Centricon centrifugal filter device with Millipore ultrafiltration YM-10 filter. The dialyzed fractions were then concentrated and stored at ⁇ 80° C. until use.
  • TNSALP and TNSALP-hFc activity were measured using the 250 ⁇ l of 10 mM p-nitrophenyl phosphate (pNPP) as substrate in 1 M diethanolamine, pH 9.8, containing 1 mM magnesium chloride, 0.02 mM zinc chloride, and incubated at 37° C.
  • the time-dependent increase in absorbance at 405 nm (reflecting p-nitrophenolate production) was measured on a plate spectrophotometer.
  • One unit of activity was defined as the quantity of enzyme that catalyzed the hydrolysis of 1 ⁇ mol substrate in 1 minute.
  • Table 1 below provides the data analyses of the pharmacokinetics.
  • TNSALP-hFc enzyme by intravenously (i.v), subcutaneously (s.c), and intraperitoneally (i.p) methods, and those administration dose concentration was fixed by 10 U/g body weight ( FIG. 4 ).
  • the blood samples were collected to measure the level of TNSALP-hFc activity respective time course (0-48 hours).
  • the peak concentration (Cmax) and concentration peak time (Tmax) were measured by original data.
  • the area under the curve (AUC) was obtained with use of the lin-lin trapezoidal rule.
  • the terminal elimination rate constant (ke) was calculated by log-linear regression of the final data points.
  • the apparent elimination half-life time (T1 ⁇ 2) was calculated as follows: 0.693/ke.
  • the mean residence time (MRT) was calculated to divide the area under the first moment curve by the AUC.
  • the total clearance (CL) was calculated to divide the dose concentration by the AUC.
  • the steady-state distribution volume (Vd) was calculated to divide the CL by the MRT.
  • the bioavailability was calculated to divide the AUC of each administration method by the AUC of intravenous method. Those parameters were followed by actual TNSALP-hFc activity of each time point. The data for the parameters are found in Table 1 hereinbelow and are represented graphically in FIG. 4 .
  • nucleotide base sequence is found in SEQ ID NO:1 and the derived amino acid residue sequence is provided in SEQ ID NO:2.
  • Another aspect of the invention provides a composition comprising a nucleotide sequence as set forth in SEQ ID NO:1.
  • the invention provides for a method for treating a metabolic disorder, such as HPP, in a fetus or embryo were a protein having a sequence as set forth in SEQ ID NO:2 is administered to a pregnant mother.
  • the fusion protein comprises a Fc fragment of IgG1 and a soluable TNSALP.
  • the protein crosses the placenta of the mother and enters the fetal blood stream.
  • the protein is taken up into fetal tissue such that the TNSALP restores normal metabolic activity in the fetus.
  • An isolated polypeptide of this invention can be formulated into a composition as a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein or antigen) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be prepared from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine, and the like.
  • a composition of this invention can be administered in a manner compatible with the formulation for the composition, and in such an amount as is effective to induce an antibody-producing immune response.
  • the quantity of composition to be administered to achieve a desired result depends on the judgment of the practitioner and is peculiar to each individual host mammal, but are well known for laboratory hosts such as mice, rats, rabbits, goats and the like.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Transplacental enzyme replacement therapy (ERT) is disclosed for deficiency of a polypeptide such as a tissue-nonspecific alkaline phosphatase (TNSALP) by administering a pharmaceutical composition that comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion, to a pregnant animal whose fetus or embryo is in need of such therapy. Also contemplated is a method for treating a metabolic disorder, such as HPP, in a fetus or embryo where a fusion protein that comprises a Fc fragment of an IgG1 antibody peptide-bonded to TNSALP is administered to a pregnant mother. The protein crosses the placenta of the mother and enters the fetal blood stream. The protein is taken up into fetal tissue such that the TNSALP restores normal metabolic activity in the fetus.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application for patent is a continuation-in-part and claims priority to U.S. patent application Ser. No. 11/769,693, recently allowed, which was filed on Jun. 27, 2007 and claims priority to U.S. Provisional Patent Application No. 60/805,954, which was filed on Jun. 27, 2006. Both disclosures are incorporated by reference.
REFERENCE TO SEQUENCE LISTING
This application contains a Sequence Listing in paper and computer readable form which are the same and are hereby incorporated by reference in their entirety. The nucleic and amino acid sequences listed in the Sequence Listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
BACKGROUND OF THE INVENTION
Recent advances in the medical arts have enabled enzyme replacement therapies (ERTs) for a number of metabolic diseases. Those diseases include Gaucher, Krabbe, Fabry and Pompe diseases, as well as various mucopolysaccharidoses (MPS) and hypophosphatasia (HPP).
HPP is an inherited metabolic disorder that features rickets or osteomalacia caused by deficiency of tissue-nonspecific alkaline phosphatase (TNSALP; EC 3.1.3.1). TNSALP is an ubiquitous, cytosol-insoluble plasma membrane-bound enzyme. The human enzyme contains 524 amino acid residues, and the sequence is available on the UniProtKB/Swiss-Prot data base under the designation “PPBT-Human P05186”.
Hypophosphatasia is an inherited metabolic disorder of defective bone mineralization caused by deficiency of the TNSALP. Clinical severity is remarkably variable, ranging from death in utero to merely premature loss of dentition in adult life. Despite the presence of TNSALP in bone, kidney, liver, and adrenal tissue in healthy individuals, clinical manifestations in patients with hypophosphatasia are limited to defective skeletal mineralization that manifests as rickets in infants and children and osteomalacia in adults.
In the most pernicious form of hypophosphatasia, the perinatal lethal variant, profound skeletal hypomineralization results in caput membranaceum with shortened and deformed limbs noted. Some affected neonates survive for several days or weeks. The neonates often succumb to respiratory failure brought on by pulmonary hypoplasia and structural failure of the weakened skeleton from demineralization.
Prenatal therapy for inborn errors of metabolism remains an unmet challenge. Most cases of perinatal HPP with severe skeletal hypomineralization result in stillbirth or postnatal lethality. Over 50% of the patients with an infantile form of the condition die within the next few months. Advanced ultrasonography made in utero diagnosis of severe skeletal dysplasia including HPP feasible.
Acidic amino acid (AAA) oligopeptides bind specifically to bone matrix, hydroxyapatite calcium site, and tagging a therapeutic agent, namely TNSALP, with AAA markedly enhances delivery of the agent to bone [Nishioka et al., (2006) Mol Genet Metab, 88 (3):244-255]. ERT has been successively shown by a deca-Asp (D10)-tagged TNSALP (sALP-FcD10) in a HPP murine model (similar to the infantile form in human patients) to lead to marked clinical and pathological improvement [Milian et al., (2008) J Bone Miner Res, 23 (6):777-787]. The sALP-FcD10 enzyme is now used in Phase I and II clinical trials for HPP patients, resulting in substantial reversal of bone hypomineralization [Whyte et al., Hypophosphatasia: Treatment of Life-Threatening Disease Using Bone-Targeted Human Recombinant Tissue Non-Specific Alkaline Phosphatase (2009) ACR/ARHP Scientific Meeting, found at acr.confex.com/acr/2009/webprogram/Paper12463.html. This sALP-FcD10 enzyme also includes the Fc region of human IgG at the C-terminus of the enzyme for purification purposes.
Recently, Grubb et al. showed that Fc-conjugated β-glucuronidase, infused into pregnant mice, was transported across the placenta, indicating a potential application for prenatal therapy [Grubb et al., (2008) Proc Natl Acad Sci U.S.A., 105(24):8375-8380]. β-glucuronidase (GUS) is a cytosol- and water-soluble, sialic acid-containing glycoprotein enzyme that catalyzes breakdown of complex carbohydrates. Maternal IgG is transported transplacentally by the neonatal Fc receptor, which recognizes the Fc domain of IgG and mediates transcytosis from maternal to fetal circulation.
SUMMARY OF THE INVENTION
The inventors have made the surprising discovery that polypeptides that are linked to an immunoglobulin fraction-crystallizable domain (Fc-domain) are able to cross the placenta and to enter the circulation of the fetus. Thus, one aspect of the invention contemplates a fusion protein comprised of a polypeptide peptide-bonded to a Fc-domain. A preferred polypeptide has a therapeutic use, such as a metabolic enzyme. A more preferred polypeptide is a cytosol-soluble (water-soluble) portion of a membrane-bound enzyme. A most preferred polypeptide is a tissue-nonspecific alkaline phosphatase (TNSALP).
Another aspect of the invention contemplates a pharmaceutical composition that comprises an effective amount of an above-described fusion protein dissolved or dispersed in a pharmaceutically acceptable carrier. Such a carrier is typically an isotonic aqueous buffer.
Yet another aspect of the invention contemplates transplacental enzyme replacement therapy (ERT) for deficiency of a polypeptide such a TNSALP by administering a before-described pharmaceutical composition to a pregnant animal whose fetus or embryo is in need of such therapy. An exemplary fusion protein of such a composition comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion.
Administration may be by any route, preferably intravenous or intraperitoneal administration of the fusion protein. Inborn errors of metabolism comprise diseases, which include MPS (such as MPS VII) and hyphosphatasia. The fusion protein (also some times referred to herein as a chimeric polypeptide) has a therapeutic domain and a Fc-domain as described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
In the accompanying drawings, which form a part of the specification and are to be read in conjunction therewith:
FIG. 1 is a graphic representation of the results of transplacental transfer of TNSALP-Fc after intravenous infusion into pregnant mice.
FIG. 2 is a schematic drawing showing TNSALP-hFc constructions in mammalian expression vector pCXN.
FIG. 3 is a schematic drawing showing a top view of SDS-PAGE results for purified TNSALP and TNSALP-hFc.
FIG. 4 is a series of graphs showing the pharmacokinetics of different administration of infusions by using TNSALP-hFc.
DETAILED DESCRIPTION OF THE INVENTION
Applicants discovered that the prenatal delivery of a fusion protein containing the IgG Fc-domain, which after infusion into the maternal circulation, mediates delivery of the fusion protein across the placenta into the circulation of the fetus or embryo. An embryo is often described in the human context as existing from conception to about the eighth week, whereas a fetus is often described as being from about nine weeks to birth. Specifically, the present invention contemplates a fusion protein having an IgG1 Fc peptide portion peptide bonded to a water-soluble (cytosol-soluble) portion of a biologically active polypeptide that is normally membrane-bound such as tissue-nonspecific alkaline phosphatase (TNSALP) or HMG-CoA reductase. The present invention also contemplates a composition containing an effective amount of the fusion protein dissolved or dispersed in a pharmaceutically acceptable carrier. A method of treating a deficiency of that biologically active polypeptide in a fetus or embryo contemplates administering the pharmaceutical composition to the pregnant animal such as a mouse or a human whose fetus or embryo is in need of the biologically active polypeptide so that the fusion protein crosses the placenta.
A contemplated fusion protein is dissolved, dispersed or admixed in a composition that is pharmaceutically acceptable and compatible with the active ingredient as is well known. The phrases “pharmaceutically acceptable” or “physiologically tolerable” refer to molecular entities and compositions that typically do not produce an allergic or similar untoward reaction, and the like, when administered to a host mammal.
Suitable carriers can take a wide variety of forms depending on the intended use and are, for example, aqueous solutions containing saline, phosphate buffered saline (PBS), dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, a composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, mineral oils, which enhance the effectiveness of the composition. A preferred embodiment contains at least about 0.01 percent to about 99 percent of an isolated fusion polypeptide of this invention as an active ingredient, typically at a concentration of about 10 to 200 mg of fusion protein per milliliter (ml) of carrier.
A contemplated composition is conventionally administered parenterally as an aqueous composition, by injection, for example, intraperitoneally, subcutaneously or intramuscularly. The administration is provided to a pregnant human patient or suitable animal host such as a chimpanzee, mouse, rat, horse, sheep, mouse, dog, goat, bovine, monkey, or the like whose fetus or embryo is in need of the biologically active polypeptide. A contemplated composition is thus typically provided as a unit dosage amount in dry form that can be readied for administration by addition and mixing of deionized or distilled or other sterile water.
The amount of fusion protein utilized in each administration is referred to as an effective amount and can vary widely, depending inter alia, upon the fusion protein, the genus of the animal to which the a fusion protein is administered, and the severity of the disease state being treated. An effective amount of a fusion protein at least temporarily improves the disease state for which the fusion protein is administered. In the illustrative example used herein, heterozygous pregnant mice were infused with 10 U/g body weight of TNSALP-hFc on embryonic days 17.5 and that administration was successful in raising the level of TNSALP circulating in the fetal mice to almost twice the amount of enzyme present in untreated mice. The amount selected as an effective amount of a fusion protein can be determined for a given animal host and disease by a skilled worker without undue experimentation.
It is advantageous to treat severely affected fetuses or embryos with enzyme replacement therapies (ERTs) before birth to minimize the deficiency in utero such as bone hypomineralization. The disclosure provided hereinafter illustrate that the present invention can be applied to the prenatal treatment of hypophosphatasia (HPP) as an illustrative fetal or embryonic disease that can be so treated.
The transplacental approach can be used for the prenatal treatment of HPP, which will have a significant impact on clinical practice. To illustrate that the present invention can be applied to the prenatal treatment of HPP in a murine model, a fusion protein comprising the C-terminal, hydrophobic, membrane-spanning portion of TNSALP was expressed as a fusion protein with the IgG1 CH2—CH3 hFc portion (TNSALP-hFc). That fusion protein was compared with the untagged recombinant TNSALP for clearance from the maternal circulation and delivery to the fetus. To determine whether TNSALP-hFc could be transferred across the placenta, ALP activity in plasma of HPP newborns born from HPP heterozygous females mated with HPP heterozygous males was examined. It was observed that TNSALP-hFc, infused into pregnant mice on embryonic day 17.5, was transported across the placenta, whereas untagged TNSALP was not delivered to the fetus. These results are shown in FIG. 1.
These results can be translated into transplacental ERT because the hFc-conjugated TNSALP is already clinically investigated for ERT in HPP patients. To produce the results shown in FIG. 1, heterozygous male and female mice were mated to produce HPP offspring. Heterozygous pregnant mice were infused with 10 U/g body weight of TNSALP-hFc, untagged TNSALP, or saline on embryonic days 17.5. The pups were tested and the following was found:
A) The heterozygous pups produced by the pregnant mice treated with TNSALP-hFc increased plasma activity (3.930±0.228 U/mL n=2); however, the heterozygous pups produced by saline or untagged TNSALP infused pregnant mice had the same levels of 2.143±0.101 U/mL (n=2) and 2.009±0.075 U/mL (n=19), respectively.
B) A similar increase was observed in homozygous pups produced by treated pregnant mice. Plasma ALP levels of 1-day-old homozygous pups derived from pregnant mice treated with untagged TNSALP were not detectable (N.D.), whereas the pregnant mice, which were infused with TNSALP-hFc, produced homozygous pups that contained 50% of normal levels of plasma ALP activity (0.904±0.036 U/mL, n=3).
Thus, in one embodiment of the present invention, the C-terminus-anchorless TNSALP enzyme was produced and the secreted form tagged with CH2—CH3 hFc portion to form a fusion protein that was expressed using Chinese Hamster Ovarian (CHO) cell line and showed transplacental activity in fetus on hypophosphatasia mice with ERT. The present invention indicated that the enzyme with IgG1 CH2—CH3 hFc portion is effective as a therapeutic agent transplacentally. This method is applicable to other proteins whose deficiency leads to the other human disorders with deficiency of an enzyme such as fetal hypolipidemia using the C-terminal membrane anchor truncated HMG-CoA reductase. See, U.S. Pat. No. 5,460,949 for a useful sequence.
Here, first, the TNSALP and TNSALP-hFc were purified by the following two-step column procedure. Tris buffer was 25 mM Tris-HCl, pH 8.0, containing 0.1 mM magnesium chloride and 0.01 mM zinc chloride. Unless stated otherwise, all steps were performed at 4° C. The following procedure was followed:
Step 1. The medium-containing enzyme was filtered through a 0.2 μm filter and then dialyzed against Tris buffer using Amicon stirred-cell ultrafiltration unit with Millipore ultrafiltration membrane YM-30.
Step 2. The dialyzed medium was applied to a column of DEAE-Sepharose equilibrated with Tris buffer. The column was first washed with Tris buffer and then the enzyme was eluted with 0 to 0.4 M NaCl in a linear gradient.
Step 3. The active eluted fractions were pooled and dialyzed against Tris buffer containing 0.1 M NaCl by using Centricon centrifugal filter device with Millipore ultrafiltration YM-10 filter. The dialyzed fractions were then concentrated for Step 4.
Step 4. The concentrated enzyme was applied to a column of Sephacryl S-400-HR equilibrated with Tris buffer containing 0.1 M NaCl. The enzyme was eluted with Tris buffer containing 0.1 M NaCl.
Step 5. The active eluted fractions were pooled and dialyzed against Tris buffer containing 0.1 M NaCl by using Centricon centrifugal filter device with Millipore ultrafiltration YM-10 filter. The dialyzed fractions were then concentrated and stored at −80° C. until use.
To characterize the purified TNSALP-hFc, a polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) was performed, followed by silver staining. This is shown in FIG. 3.
The TNSALP and TNSALP-hFc activity were measured using the 250 μl of 10 mM p-nitrophenyl phosphate (pNPP) as substrate in 1 M diethanolamine, pH 9.8, containing 1 mM magnesium chloride, 0.02 mM zinc chloride, and incubated at 37° C. The time-dependent increase in absorbance at 405 nm (reflecting p-nitrophenolate production) was measured on a plate spectrophotometer. One unit of activity was defined as the quantity of enzyme that catalyzed the hydrolysis of 1 μmol substrate in 1 minute.
Table 1 below provides the data analyses of the pharmacokinetics. One month-old wild type mice were infused with TNSALP-hFc enzyme by intravenously (i.v), subcutaneously (s.c), and intraperitoneally (i.p) methods, and those administration dose concentration was fixed by 10 U/g body weight (FIG. 4). After infusion, the blood samples were collected to measure the level of TNSALP-hFc activity respective time course (0-48 hours). The peak concentration (Cmax) and concentration peak time (Tmax) were measured by original data. The area under the curve (AUC) was obtained with use of the lin-lin trapezoidal rule. The terminal elimination rate constant (ke) was calculated by log-linear regression of the final data points. The apparent elimination half-life time (T½) was calculated as follows: 0.693/ke. The mean residence time (MRT) was calculated to divide the area under the first moment curve by the AUC. The total clearance (CL) was calculated to divide the dose concentration by the AUC. The steady-state distribution volume (Vd) was calculated to divide the CL by the MRT. The bioavailability was calculated to divide the AUC of each administration method by the AUC of intravenous method. Those parameters were followed by actual TNSALP-hFc activity of each time point. The data for the parameters are found in Table 1 hereinbelow and are represented graphically in FIG. 4.
TABLE 1
Pharmacokinetics Parameter
Mice Age
1 month-old
Enzyme TNSALP-hFc
injection manner i.v s.c i.p
Dose (U/g) 10 10 10
T½ (hr) 29.9 54.1 33.9
Tmax (hr) 0.5 24 1
Cmax (U/mL) 50.9 29.8 67
AUC (U/mL * hr) 139.4 1172.3 1866.9
Bioavailability (%) 100 840.7 1338.9
MRT (mean residence time) (hr) 11.8 16.7 14.5
Vd (mL/g) 0.848 0.143 0.078
CL (mL/(hr * g)) 0.0717 0.0085 0.0054
As provided herein, the nucleotide base sequence is found in SEQ ID NO:1 and the derived amino acid residue sequence is provided in SEQ ID NO:2. Another aspect of the invention provides a composition comprising a nucleotide sequence as set forth in SEQ ID NO:1. Another aspect of the invention provides a composition comprising a polypeptide as set forth in SEQ IS NO:2.
The invention provides for a method for treating a metabolic disorder, such as HPP, in a fetus or embryo were a protein having a sequence as set forth in SEQ ID NO:2 is administered to a pregnant mother. The fusion protein comprises a Fc fragment of IgG1 and a soluable TNSALP. The protein crosses the placenta of the mother and enters the fetal blood stream. The protein is taken up into fetal tissue such that the TNSALP restores normal metabolic activity in the fetus.
An isolated polypeptide of this invention can be formulated into a composition as a neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein or antigen) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be prepared from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine, and the like.
A composition of this invention can be administered in a manner compatible with the formulation for the composition, and in such an amount as is effective to induce an antibody-producing immune response. The quantity of composition to be administered to achieve a desired result depends on the judgment of the practitioner and is peculiar to each individual host mammal, but are well known for laboratory hosts such as mice, rats, rabbits, goats and the like.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Because many possible embodiments can be made of the invention without departing from the scope thereof, it is to be understood that all matter herein set forth is to be interpreted as illustrative, and not in a limiting sense.

Claims (2)

What is claimed is:
1. A method for treating hypophosphatasia in a fetus or embryo comprising the step of parenterally delivering a fusion protein having the sequence as set forth in SEQ ID NO:2 to a pregnant mother, wherein said fusion protein comprises a Fc fragment of an IgG antibody and a tissue-nonspecific alkaline phosphatase enzyme, and wherein said fusion protein crosses a placenta of said mother and enters said fetus's or embryo's blood stream, and wherein said fusion protein is taken up into fetal or embryonic tissue such that said enzyme restores normal mineralization activity in said fetus or embryo.
2. The method of claim 1, wherein said fusion protein is delivered intraperitoneally or subcutaneously.
US13/007,772 2006-06-27 2011-01-17 Prenatal enzyme replacement therapy for hypophosphatasia Active US8784833B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/007,772 US8784833B2 (en) 2006-06-27 2011-01-17 Prenatal enzyme replacement therapy for hypophosphatasia
PCT/US2012/021507 WO2012099851A2 (en) 2011-01-17 2012-01-17 Prenatal enzyme replacement therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80595406P 2006-06-27 2006-06-27
US11/769,693 US7871624B2 (en) 2006-06-27 2007-06-27 Chimeral polypeptide composition for cross-placenta delivery
US13/007,772 US8784833B2 (en) 2006-06-27 2011-01-17 Prenatal enzyme replacement therapy for hypophosphatasia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/769,693 Continuation-In-Part US7871624B2 (en) 2006-06-27 2007-06-27 Chimeral polypeptide composition for cross-placenta delivery

Publications (2)

Publication Number Publication Date
US20110300143A1 US20110300143A1 (en) 2011-12-08
US8784833B2 true US8784833B2 (en) 2014-07-22

Family

ID=46516325

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/007,772 Active US8784833B2 (en) 2006-06-27 2011-01-17 Prenatal enzyme replacement therapy for hypophosphatasia

Country Status (2)

Country Link
US (1) US8784833B2 (en)
WO (1) WO2012099851A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365023T3 (en) 2004-04-21 2011-09-20 Enobia Pharma Inc. CONJUGATES OF BONE ADMINISTRATION AND METHOD OF USE OF THE SAME TO DIRECT BONE PROTEINS.
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
BR112012027765A2 (en) 2010-04-30 2019-09-24 Enobia Pharma Inc methods, compositions and kits for treating matrix mineralization disorders.
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CN110719786A (en) 2017-03-31 2020-01-21 阿雷克森制药公司 Methods for treating Hypophosphatasia (HPP) in adults and adolescents
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
WO2001036603A2 (en) 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20050142140A1 (en) * 2002-06-07 2005-06-30 Steffen Massberg Immunoadhesin comprising a glycoprotein VI domain
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US20080025995A1 (en) * 2006-06-27 2008-01-31 Grubb Jeffrey H Cross-Placenta Delivery System
US20100297119A1 (en) * 2007-05-11 2010-11-25 Enobia Pharma Inc. Bone targeted alkaline phosphatase, kits and methods of use thereof
US20110300143A1 (en) 2006-06-27 2011-12-08 Saint Louis University Prenatal enzyme replacement therapy

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
WO2001036603A2 (en) 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20050142140A1 (en) * 2002-06-07 2005-06-30 Steffen Massberg Immunoadhesin comprising a glycoprotein VI domain
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US7943126B2 (en) * 2005-10-11 2011-05-17 Saint Louis University Compositions and methods for treating hypophosphatasia
US20080025995A1 (en) * 2006-06-27 2008-01-31 Grubb Jeffrey H Cross-Placenta Delivery System
US7871624B2 (en) * 2006-06-27 2011-01-18 Saint Louis University Chimeral polypeptide composition for cross-placenta delivery
US20110300143A1 (en) 2006-06-27 2011-12-08 Saint Louis University Prenatal enzyme replacement therapy
US20100297119A1 (en) * 2007-05-11 2010-11-25 Enobia Pharma Inc. Bone targeted alkaline phosphatase, kits and methods of use thereof

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Ashkenazi, et al., Immunoadhesins as research tools and therapeutic agents, Curr Opin Immunol. Apr. 1997; 9:195-200.
Becker ,et al., Kinetic Data of in-vivo labeled granulocytes in humans with a murine Tc-99m-labelled monoclonal antibody, Eur J Nucl Med, 1989, 15:361-366, abstract only.
Brady, R. O., "Enzyme Replacement for Lysosomal Disease," Annu. Rev. Med., 57: 283-296, 2006.
Chinese Hamster Ovary Cell Line American Type Culture Collection, ATCC CRL 9618, printed Jun. 19, 2012 from world wide web. atcc. org.
Gheti, et al., Multiple Roles for the Major Histocompatibility Complex Class I-Related Receptor FcRn. Annu. Rev. Immunol. (2000) 18:739-766.
Glaser, et al., Beta-glucuronidase deficiency mucopolysaccharidosis: methods for enzymatic diagnosis. (1973) Journal Lab. Clin. Med. 82: 969-977.
Grubb, et al., Infused Fc-tagged beta-glucoronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice, PNAS, Jun. 17, 2008, vol. 105, No. 24.
Grubb, et al., Infused Fc-tagged β-glucoronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice, PNAS, Jun. 17, 2008, vol. 105, No. 24.
Hickman, et al., A recognition marker required for uptake of a lysosomal enzyme by cultured fibroblasts. 1974, Biochemical and Biophysical Research Communications vol. 57, Issue 1, 55-61.
Islam, et al., C-terminal Processing of Human beta-glucuronidase. (1993) Journal of Biological Chemistry vol. 268 (30):22627-22633.
Islam, et al., C-terminal Processing of Human β-glucuronidase. (1993) Journal of Biological Chemistry vol. 268 (30):22627-22633.
Laemmli, Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4, (1970) Nature (London) 227, 680-685.
Lebowitz, et al., Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice, PNAS, Mar. 2, 2004, vol. 101, No. 9, 3083-3088.
Millan et al, Enzyme Replacement Therapy for Murine Hypophosphatasia, (2008) Journal of Bone and Mineral Research, vol. 23(6):777-787.
Nelson, et al. Mucopolysaccharisosis VII presenting as nonimmune hydrops fetalis, (Oct. 1982) Journal of Pediatrics, 101:574.
Neufeld, E. F., et al (2001) The Metabolic and Molecular Bases of Inherited Disease, eds. Scriver, C. R., Beaudet, A. L., Sly, W. S., & Valle, D. (McGraw-Hill, New York), vol. III, 8th edition, pp. 3421-3451.
Nishioka et al, Enhancement of drug delivery to bone: Charactereization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide, Molecular Genetics and Metabolism, 2006, 88(3):244-255.
Niwa, et al., Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, (1991) 193-200.
Orii, et al., Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice, (2005) Molecular Therapy vol. 12, 2, 345-352.
Ulmasov, et al., Purification and kinetic analysis of recombinant CAXII, a membrane carbonic anhydrase overexpressed in certain cancers. PNAS (2000), vol. 97 No. 26 14212-14217.
Von Figura, et al., Lysosomal enzymes and their receptors. (1986)., Annu. Rev. Biochem. 55: 167-193.
Whyte et al., Hypophosphatasia: Treatment of Life-Threatening Disease Using Bone-Targeted Human Recombinant Tissue Non-Specific Alkaline Phosphatase (2009) ACR/ARHP Scientific Meeting, found at http://acr.confex.com/acr/2009/webprogram/Paper12463.html.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders

Also Published As

Publication number Publication date
US20110300143A1 (en) 2011-12-08
WO2012099851A2 (en) 2012-07-26
WO2012099851A3 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
US8784833B2 (en) Prenatal enzyme replacement therapy for hypophosphatasia
EP1981546B1 (en) Enzyme replacement therapy for treating lysosomal storage diseases
AU2005211775B2 (en) Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
US8569032B2 (en) Proteins having acquired A-galactosidase activity
US20030017977A1 (en) Methods of treating inflammatory skin diseases
KR20230054482A (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
EP3439702B1 (en) Conjugated c1 esterase inhibitor and uses thereof
US11345904B2 (en) Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
JP2019506408A (en) Use of CD24 protein to treat leptin deficiency conditions
JP2017531632A (en) Methods for treating mucopolysaccharidosis type IIIB (MPSIIIB)
US20160272694A1 (en) Compositions and methods for the treatment of ectodermal dysplasia
CA3202364A1 (en) Dsg2 compositions and methods for the treatment of covid-19
Brooks et al. Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model
US20130039934A1 (en) Treatment of ige-mediated disease
RU2811100C1 (en) Compound containing therapeutic enzyme and transport element connected to each other directly or by using linker
EP4389772A1 (en) Targeted delivery of therapeutic enzymes
US20240350653A1 (en) Targeted delivery of therapeutic enzymes
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
JP2018534917A (en) Modified iduronic acid 2-sulfatase and its production
EA044641B1 (en) COMPOUND CONTAINING A THERAPEUTIC ENZYME AND A TRANSPORT ELEMENT CONNECTED TO EACH OTHER DIRECTLY OR BY USING A LINKER
KR20240110819A (en) DSG2 compositions and methods

Legal Events

Date Code Title Description
AS Assignment

Owner name: SAINT LOUIS UNIVERSITY, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SLY, WILLIAM S.;GRUBB, JEFFREY H.;TOMATSU, SHUNJI;AND OTHERS;SIGNING DATES FROM 20110402 TO 20110722;REEL/FRAME:026762/0263

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

FEPP Fee payment procedure

Free format text: SURCHARGE FOR LATE PAYMENT, SMALL ENTITY (ORIGINAL EVENT CODE: M2554)

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551)

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, SMALL ENTITY (ORIGINAL EVENT CODE: M2555); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8